The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Knee Osteoarthritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market.
Some of the key takeaways from the Knee Osteoarthritis Pipeline Report:
Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years.
Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Knee Osteoarthritis treatment
Emerging Knee Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.
In September 2024, Cytonics has announced the completion of subject enrollment for its Phase I clinical trial of CYT-108, a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor. The company initiated this Phase I trial in July, which is a first-in-human, multicenter, six-month, double-blind, randomized controlled trial (RCT) aimed at evaluating the safety and efficacy of CYT-108 in patients with unilateral, mild-to-moderate primary OA of the knee.
In June 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage company focused on macrophage reprogramming immunotherapy, announced a positive interim data update from a Phase I/II investigator-initiated clinical trial of Allocetra™ in patients with end-stage knee osteoarthritis who were candidates for knee replacement surgery.
Knee Osteoarthritis Overview
Knee osteoarthritis is a degenerative joint disease that occurs when the protective cartilage in the knee joint wears down over time. This leads to pain, stiffness, swelling, and reduced mobility. The condition is most common in older adults but can also affect younger individuals due to injury or genetic factors. Risk factors include age, obesity, previous knee injuries, and family history. Symptoms often worsen with activity and improve with rest. Treatment options include physical therapy, pain management with medications, lifestyle changes like weight loss, and in severe cases, surgical interventions such as knee replacement.
Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight
Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include:
M6495: Merck KGaA
PPV 06: Peptinov
LG00034053: LG Chem
StroMel: Akan Bioscience
TTAX03: BioTissue,Inc.
EP-104IAR: Eupraxia Pharmaceuticals Inc.
OLP 1002: OliPass Corporation
JTA-004: Bone Therapeutics
X 0002: Techfields Pharma
Lorecivivint: Biosplice Therapeutics
Knee Osteoarthritis Route of Administration
Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Knee Osteoarthritis Molecule Type
Knee Osteoarthritis Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Knee Osteoarthritis Pipeline Therapeutics Assessment
Knee Osteoarthritis Assessment by Product Type
Knee Osteoarthritis By Stage and Product Type
Knee Osteoarthritis Assessment by Route of Administration
Knee Osteoarthritis By Stage and Route of Administration
Knee Osteoarthritis Assessment by Molecule Type
Knee Osteoarthritis by Stage and Molecule Type
DelveInsight’s Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies
Some of the key companies in the Knee Osteoarthritis Therapeutics Market include:
Key companies developing therapies for Knee Osteoarthritis are – Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others.
Knee Osteoarthritis Pipeline Analysis:
The Knee Osteoarthritis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies
Knee Osteoarthritis Pipeline Market Drivers
Increase in prevalence of Osteoarthritis, robust Knee Osteoarthritis Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market.
Knee Osteoarthritis Pipeline Market Barriers
However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth.
Scope of Knee Osteoarthritis Pipeline Drug Insight
Coverage: Global
Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others
Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others
Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers
Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials
Table of Contents
1. Knee Osteoarthritis Report Introduction
2. Knee Osteoarthritis Executive Summary
3. Knee Osteoarthritis Overview
4. Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment
5. Knee Osteoarthritis Pipeline Therapeutics
6. Knee Osteoarthritis Late Stage Products (Phase II/III)
7. Knee Osteoarthritis Mid Stage Products (Phase II)
8. Knee Osteoarthritis Early Stage Products (Phase I)
9. Knee Osteoarthritis Preclinical Stage Products
10. Knee Osteoarthritis Therapeutics Assessment
11. Knee Osteoarthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Knee Osteoarthritis Key Companies
14. Knee Osteoarthritis Key Products
15. Knee Osteoarthritis Unmet Needs
16 . Knee Osteoarthritis Market Drivers and Barriers
17. Knee Osteoarthritis Future Perspectives and Conclusion
18. Knee Osteoarthritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
